tert-Butyl piperazine-1-carboxylate → 4-Isoquinolin-7-yl-piperazine-1-carboxylic acid tert-butyl ester
Reaction equation
[CH:1]1[C:10]2[C:5](=[CH:6][CH:7]=[C:8](OS(C(F)(F)F)(=O)=O)[CH:9]=2)[CH:4]=[CH:3][N:2]=1.[C:19]([N:26]1[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]1)([O:21][C:22]([CH3:25])([CH3:24])[CH3:23])=[O:20]>>[C:22]([O:21][C:19]([N:26]1[CH2:31][CH2:30][N:29]([C:8]2[CH:9]=[C:10]3[C:5]([CH:4]=[CH:3][N:2]=[CH:1]3)=[CH:6][CH:7]=2)[CH2:28][CH2:27]1)=[O:20])([CH3:25])([CH3:23])[CH3:24]Participants
3
Procedure
The product from step (a) above (300 mg, 1.1 mmol) and 1-BOC-piperazine (307 mg, 1.6 mmol, Aldrich) was reacted under the conditions of Example 132b to give the title compound as yellow amorphous solid, which was used for the next step. MS (ESI, pos. ion) m/z: 314 (M+1).
Sources & evidence
- ORD record
- ord-b5761fb5bdce4743b73387cdeb598e04
- Source dataset
- uspto-grants-2011_09
- Patent number
- US08026241B2
Reaction notes
Loading…